Research Topics
Genomes and GenesSpecies | J CreaneySummaryAffiliation: University of Western Australia Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Auto-antibodies to β-F1-ATPase and vimentin in malignant mesotheliomaJenette Creaney
National Centre for Asbestos Related Diseases, University of Western Australia, School of Medicine and Pharmacology, Nedlands, Western Australia, Australia
PLoS ONE 6:e26515. 2011..Therefore antibodies to neither vimentin nor ß-F1-ATPase are useful for differential diagnosis of MM, however high antibody levels to ß-F1-ATPase may be associated with increased survival and this warrants further investigation...- Overexpression and altered glycosylation of MUC1 in malignant mesotheliomaJ Creaney
National Research Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, University of Western Australia, Perth, Western Australia, Australia
Br J Cancer 98:1562-9. 2008.... 
Serum and pleural fluid biomarkers for mesotheliomaJenette Creaney
National Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, University of Western Australia, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia
Curr Opin Pulm Med 15:366-70. 2009..With the incidence of malignant mesothelioma expected to increase, it is timely to review the current status of biomarkers in this field...
Combined CA125 and mesothelin levels for the diagnosis of malignant mesotheliomaJenette Creaney
National Research Centre for Asbestos Related Diseases, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia
Chest 132:1239-46. 2007..The purpose of this study was to study the mesothelin biomarker in a large patient cohort and to determine if another biomarker, CA125, improves on the sensitivity of mesothelin in the diagnosis of mesothelioma...- Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesotheliomaJenette Creaney
Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Verdun Ave, Nedlands 6009, Western Australia, Australia
Thorax 62:569-76. 2007.... - Serum mesothelin for early detection of asbestos-induced cancer malignant mesotheliomaJenette Creaney
National Research Centre for Asbestos Related Disease, Sir Charles Gairdner Hospital, 2School of Medicine and Pharmacology, University of Western Australia, QEII Medical Centre, Nedlands, Western Australia, Australia
Cancer Epidemiol Biomarkers Prev 19:2238-46. 2010..In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma... - Sensitivity of urinary mesothelin in patients with malignant mesotheliomaJenette Creaney
National Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
J Thorac Oncol 5:1461-6. 2010.... - Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related proteinJenette Creaney
School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G Block, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia
Hematol Oncol Clin North Am 19:1025-40, v. 2005.... - Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burdenJenette Creaney
National Research Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Clin Cancer Res 17:1181-9. 2011..To examine the clinical utility of soluble mesothelin in patients with malignant pleural mesothelioma... - Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?Jenette Creaney
National Research Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, 4th Floor, G Block, Verdun St, Nedlands, WA 6009, Australia
Lung Cancer 74:55-60. 2011..As there is some concern about the sensitivity of osteopontin in serum versus plasma, we compared them in the same patient population to mesothelin... - Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesotheliomaJenette Creaney
National Research Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia
J Thorac Oncol 3:851-7. 2008.... - Soluble mesothelin related protein in mesotheliomaJenette Creaney
School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Wedlands, WA, Australia
J Thorac Oncol 1:172-4. 2006 - p53 autoantibodies in patients with malignant mesothelioma: stability through disease progressionJ Creaney
Western Australian Institute for Medical Research and University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, 4th Floor, G Block, Nedlands, Perth, 6009, Western Australia
Br J Cancer 84:52-6. 2001..The occurrence of anti-p53 antibodies does not serve as either a useful prognostic or diagnostic indicator in MM... - Soluble mesothelin-related protein--a blood test for mesotheliomaBruce W S Robinson
University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Perth, WA, Australia
Lung Cancer 49:S109-11. 2005..SMRP should also be useful for monitoring disease progression, and importantly, may prove useful for screening asbestos-exposed individuals for early MM... - Mesothelin-family proteins and diagnosis of mesotheliomaBruce W S Robinson
University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Western Australia, Perth, Australia
Lancet 362:1612-6. 2003..Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals... - Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesotheliomaAlex Powell
School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Perth, Western Australia
Lung Cancer 52:189-97. 2006..We therefore evaluated the effect of an autologous MM tumor cell lysate, given s.c. with recombinant granulocyte-macrophage colony stimulating factor (GM-CSF), on anti-tumor immunity in patients with MM... - Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort studyEun Kee Park
Research and Education Unit, Dust Disease Board, Level 2, 82 Elizabeth Street, Sydney, NSW 2000, Australia
Am J Respir Crit Care Med 178:832-7. 2008..Soluble mesothelin-related protein (SMRP) is raised in epithelial-type malignant mesothelioma (MM), but the utility of SMRP in screening for MM is unknown... - A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusionsAndrew J Holloway
Ian Potter Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia
Clin Cancer Res 12:5129-35. 2006..We have therefore designed a gene expression-based test to classify the primary tumor causing a malignant pleural effusion, using cells collected from the effusion itself... - Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control studyOluf Dimitri Roe
Department of Oncology, St Olavs Hospital, Trondheim University Hospital, Norway
Lung Cancer 61:235-43. 2008..Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression...